KPV Spray10mg
KPV Spray Canada — Nasal Spray
Tripeptide Research Compound — Nasal Spray
KPV is a synthetic tripeptide composed of lysine–proline–valine and represents a fragment derived from the alpha-melanocyte–stimulating hormone (α-MSH) sequence. It is developed for controlled laboratory research involving peptide-mediated signaling systems.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
KPV is a synthetic tripeptide composed of lysine–proline–valine and represents a fragment derived from the alpha-melanocyte–stimulating hormone (α-MSH) sequence. It is developed for controlled laboratory research involving peptide-mediated signaling systems.
In scientific literature, KPV is studied in experimental models examining inflammatory signaling pathways, cytokine-associated regulatory frameworks, and epithelial interaction systems under in vitro and preclinical research conditions.
KPV is the C-terminal tripeptide fragment of α-MSH and has been evaluated in research focused on immune-related signaling pathways and epithelial system interaction models. Experimental studies examine its interaction within inflammatory regulatory frameworks and peptide-mediated signaling systems in controlled laboratory environments.
Research publications have explored its pathway-level regulatory characteristics and signaling behavior under structured experimental conditions.
The parent peptide α-MSH was originally studied for its role in melanocortin signaling systems. Subsequent biochemical investigations identified smaller active fragments, including KPV, for further experimental evaluation.
Research expanded into models exploring peptide fragment interaction within inflammatory and epithelial signaling systems under laboratory conditions.
Laboratory investigations into KPV have focused on inflammatory signaling pathway models and epithelial system regulatory frameworks. Research environments evaluate peptide interaction within cytokine-associated signaling systems and cellular response mechanisms under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on inflammatory. This heading marks where KPV Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on cytokine. This heading marks where KPV Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on epithelial or interaction. This heading marks where KPV Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Xiao 2017, Dalmasso 2008. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published between 2008 and 2017 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for KPV Spray, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
KPV Spray is also referred to as KPV.
KPV Spray is commonly described online in connection with stronger immune function and resistance to infection. In the research literature the same compound is filed under inflammatory signaling pathway models, cytokine regulatory framework studies and epithelial interaction research systems.
The 3 papers cited on this page, published between 2008 and 2017 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for KPV Spray is per lot, not per product. The current 10mg lot KPV-CA-26I-10 returned 99.103% purity, 11.56 mg measured, 115.6% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for KPV Spray. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy KPV Spray in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
KPV Spray ships as a prepared solution rather than as lyophilized powder, so it is already past the point at which a powder would be reconstituted. That shortens handling but tightens storage: a compound in solution is less stable than the same compound dry, and refrigeration from arrival onward is the relevant control.
The stability window for a solution is shorter than the shelf life of a sealed lyophilized vial of the same compound. Records for laboratory work in this format should note the date the unit was opened, not only the date it was received.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 30mg of lyophilized KPV. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.
PubMedDrug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
PubMedPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
